APA (7th ed.) Citation

J, N., S, P., Y, R., JY, L., CH, F., GF, H., . . . ML, J. (2026). Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1. Lung cancer (Amsterdam, Netherlands), 215, 109316. https://doi.org/10.1016/j.lungcan.2026.109316

Chicago Style (17th ed.) Citation

J, Naidoo, et al. "Domvanalimab Combined with Zimberelimab as First-line Treatment in Patients with PD-L1-high, Advanced Non-small Cell Lung Cancer: Results from the Randomized Phase 2 ARC-10 Study, Part1." Lung Cancer (Amsterdam, Netherlands) 215 (2026): 109316. https://doi.org/10.1016/j.lungcan.2026.109316.

MLA (9th ed.) Citation

J, Naidoo, et al. "Domvanalimab Combined with Zimberelimab as First-line Treatment in Patients with PD-L1-high, Advanced Non-small Cell Lung Cancer: Results from the Randomized Phase 2 ARC-10 Study, Part1." Lung Cancer (Amsterdam, Netherlands), vol. 215, 2026, p. 109316, https://doi.org/10.1016/j.lungcan.2026.109316.